| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03f302dac3b914c7003a809e35b95354 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2016-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e002b5b87332bf89a732720b1afdd9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1d2a2ad9095e46522f15435f66cb88f |
| publicationDate |
2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018369281-A1 |
| titleOfInvention |
Method of ameliorating side effects of sickle cell disease treatments |
| abstract |
A method of reducing a cerebral tissue pathology associated with a sickle cell disease therapy in a subject is provided using (i) a synthetic high-oxygen affinity hemoglobin-containing molecule or (ii) synthetically treated high-oxygen affinity blood. |
| priorityDate |
2015-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |